Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.
- Associated Conditions
- Type 2 Diabetes Mellitus
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
- Target Recruit Count
- 504
- Registration Number
- NCT06851962
- Locations
- 🇪🇸
Hospital Universitario Regional de Málaga, Málaga, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸Hospital General Universitario de Valencia (HGUV), Valencia, Spain
The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- International Bio service
- Target Recruit Count
- 48
- Registration Number
- NCT06243809
Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
- Conditions
- Kidney Transplant; ComplicationsDiabetes Mellitus
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 200
- Registration Number
- NCT06098625
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
- Conditions
- Kidney Transplant; ComplicationsDiabetes Mellitus
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 200
- Registration Number
- NCT06095492
- Locations
- 🇮🇳
Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon, Haryana, India
Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 106
- Registration Number
- NCT05956522
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University Phase I Clinical Research Center, Qingdao, Shandong, China
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- EMS
- Target Recruit Count
- 597
- Registration Number
- NCT05886088
- Locations
- 🇧🇷
Investigational site, Hortolândia, SP, Brazil
Cognitive Protective Effect of Newer Antidiabetic Drugs
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial
- Conditions
- Type 2 Diabetes MellitusMild Cognitive Impairment
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 324
- Registration Number
- NCT05313529
- Locations
- 🇨🇳
Department of Endocrinology, Changzhou No.2 People's Hospital, the Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
🇨🇳Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
- Conditions
- Polycystic Ovary Syndrome (PCOS)
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 75
- Registration Number
- NCT05200793
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
- Conditions
- Type 2 Diabetes MellitusCardiovascular Diseases
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 270000
- Registration Number
- NCT05073692
- Locations
- 🇺🇸
Romain S. Neugebauer, Oakland, California, United States
🇺🇸Kaiser Permanente Southern California, Pasadena, California, United States
🇺🇸Kaiser Permanente Hawaii, Honolulu, Hawaii, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.